ENB-106 is under clinical development by Ennovabio and currently in Phase III for Acute Renal Failure (ARF) (Acute Kidney Injury). According to GlobalData, Phase III drugs for Acute Renal Failure (ARF) (Acute Kidney Injury) does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the ENB-106 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ENB-106 overview
ENN-106 is under development for the treatment of diabetic retinopathy (DR), diabetic macular edema (DME), cancer, non-alcoholic steatohepatitis (NASH) and cardiac surgery-associated acute kidney injury (CSA-AKI). The drug candidate is administered through oral route. It is being developed based on eSTEM systems biology platform.
It was under development for unspecified cancer.
Ennovabio overview
Ennovabio, a pharmaceutical company that focuses on creating drugs targeting brain glioma. The company is headquartered in China.
For a complete picture of ENB-106’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
